BRPI0716997B8 - proteína ou composição de moléculas de proteína, métodos para produção e uso da mesma - Google Patents
proteína ou composição de moléculas de proteína, métodos para produção e uso da mesmaInfo
- Publication number
- BRPI0716997B8 BRPI0716997B8 BRPI0716997A BRPI0716997A BRPI0716997B8 BR PI0716997 B8 BRPI0716997 B8 BR PI0716997B8 BR PI0716997 A BRPI0716997 A BR PI0716997A BR PI0716997 A BRPI0716997 A BR PI0716997A BR PI0716997 B8 BRPI0716997 B8 BR PI0716997B8
- Authority
- BR
- Brazil
- Prior art keywords
- protein
- producing
- composition
- molecule composition
- protein molecule
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 7
- 108090000623 proteins and genes Proteins 0.000 title abstract 7
- 239000000203 mixture Substances 0.000 title abstract 4
- 238000004519 manufacturing process Methods 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 2
- 210000000601 blood cell Anatomy 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 230000013595 glycosylation Effects 0.000 abstract 1
- 238000006206 glycosylation reaction Methods 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0006—Modification of the membrane of cells, e.g. cell decoration
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1735—Mucins, e.g. human intestinal mucin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E60/00—Enabling technologies; Technologies with a potential or indirect contribution to GHG emissions mitigation
- Y02E60/10—Energy storage using batteries
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
sistema de produção totalmente humano de rendimento elevado para proteínas e anticorpos melhorados. a presente invenção refere-se a um método para a produção de uma composição de molécula proteica com um padrão de glicosilação definido, compreendendo: a introdução numa célula hospedeira, a qual é uma célula sanguínea humana imortalizada, de pelo menos um ácido nucleico codificando pelo menos uma parte da referida proteína; e b) o cultivo da referida célula hospedeira sob condições as quais permitem a produção da referida composição da molécula proteica; e c) o isolamento da referida composição de molécula proteica.
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06090162 | 2006-09-10 | ||
EP06090162.6 | 2006-09-10 | ||
EP06090171A EP1900750A1 (en) | 2006-09-18 | 2006-09-18 | Fully human high yield production system for improved antibodies |
EP06090171.7 | 2006-09-18 | ||
EP06090190A EP1911766A1 (en) | 2006-10-13 | 2006-10-13 | Use of human cells of myeloid leukaemia origin for expression of antibodies |
EP06090190.7 | 2006-10-13 | ||
EP07090094 | 2007-05-04 | ||
EP07090094.9 | 2007-05-04 | ||
PCT/EP2007/007877 WO2008028686A2 (en) | 2006-09-10 | 2007-09-10 | Use of human cells of myeloid leukaemia origin for expression of antibodies |
Publications (4)
Publication Number | Publication Date |
---|---|
BRPI0716997A2 BRPI0716997A2 (pt) | 2013-10-15 |
BRPI0716997A8 BRPI0716997A8 (pt) | 2019-02-05 |
BRPI0716997B1 BRPI0716997B1 (pt) | 2020-06-02 |
BRPI0716997B8 true BRPI0716997B8 (pt) | 2021-05-25 |
Family
ID=39157600
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0716997A BRPI0716997B8 (pt) | 2006-09-10 | 2007-09-10 | proteína ou composição de moléculas de proteína, métodos para produção e uso da mesma |
Country Status (25)
Country | Link |
---|---|
US (3) | US9051356B2 (pt) |
EP (5) | EP2428223A3 (pt) |
JP (3) | JP5767779B2 (pt) |
KR (3) | KR20150126730A (pt) |
CN (1) | CN103436574B (pt) |
AU (1) | AU2007294122B2 (pt) |
BR (1) | BRPI0716997B8 (pt) |
CA (1) | CA2662226C (pt) |
CU (1) | CU23791A3 (pt) |
CY (1) | CY1116279T1 (pt) |
DK (2) | DK2073842T4 (pt) |
EA (1) | EA017622B1 (pt) |
ES (2) | ES2620261T3 (pt) |
FI (1) | FI2073842T4 (pt) |
HR (1) | HRP20150307T1 (pt) |
IL (1) | IL197459A (pt) |
MX (1) | MX2009002388A (pt) |
NZ (1) | NZ575974A (pt) |
PL (1) | PL2073842T3 (pt) |
PT (1) | PT2073842E (pt) |
RS (1) | RS53861B1 (pt) |
SG (1) | SG174792A1 (pt) |
SI (1) | SI2073842T1 (pt) |
WO (1) | WO2008028686A2 (pt) |
ZA (1) | ZA201001903B (pt) |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3528611B2 (ja) * | 1998-07-16 | 2004-05-17 | Jfeスチール株式会社 | 結束材の切断方法及びその装置 |
BRPI0716997B8 (pt) | 2006-09-10 | 2021-05-25 | Glycotope Gmbh | proteína ou composição de moléculas de proteína, métodos para produção e uso da mesma |
PL1920781T3 (pl) | 2006-11-10 | 2015-06-30 | Glycotope Gmbh | Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów |
WO2008135259A2 (en) * | 2007-05-04 | 2008-11-13 | Glycotope Gmbh | Antibody molecule composition |
GB0812277D0 (en) * | 2008-07-04 | 2008-08-13 | Fusion Antibodies Ltd | Antibody and uses thereof |
MX2011007545A (es) | 2009-01-22 | 2011-10-28 | Momenta Pharmaceuticals Inc | N-glicanos que contienen galactosa-alfa-1,3-galactosa en productos de glicoproteina derivados de celulas de ovario de hamster chino (cho). |
EP2451935A2 (en) | 2009-07-08 | 2012-05-16 | Glycotope GmbH | Perfusion bioreactor |
EP2281844A1 (en) | 2009-07-31 | 2011-02-09 | Glycotope GmbH | MUC 1 antibodies |
WO2012016576A1 (en) | 2010-08-04 | 2012-02-09 | Glycotope Gmbh | Improved recombinant human follicle-stimulating hormone |
AU2011288464B2 (en) * | 2010-08-10 | 2015-10-29 | Glycotope Gmbh | Fab-glycosylated antibodies |
BR112013003257A2 (pt) | 2010-08-10 | 2016-06-14 | Glycotope Gmbh | anticorpos egfr humanizados. |
US9051370B2 (en) | 2010-08-10 | 2015-06-09 | Glycotope Gmbh | Humanized EGFR antibodies |
PL2655600T3 (pl) | 2010-12-21 | 2017-08-31 | Glycotope Gmbh | Sposób hodowania ludzkich komórek białaczek szpikowych i komórek od nich pochodzących |
TWI636793B (zh) | 2011-04-21 | 2018-10-01 | 西雅圖遺傳學公司 | 新穎結合劑-藥物接合物(ADCs)及其用途(二) |
EP2702077A2 (en) | 2011-04-27 | 2014-03-05 | AbbVie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
JP6433786B2 (ja) * | 2011-08-10 | 2018-12-05 | ラボラトワール フランセ デュ フラクショヌマン エ デ ビオテクノロジーLaboratoire Francais du Fractionnement et des Biotechnologies | 高度ガラクトシル化抗体 |
CA2844543A1 (en) | 2011-08-22 | 2013-02-28 | Glycotope Gmbh | Microorganisms carrying a tumor antigen |
US9334319B2 (en) | 2012-04-20 | 2016-05-10 | Abbvie Inc. | Low acidic species compositions |
US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
AU2013291964B2 (en) * | 2012-07-18 | 2017-12-14 | Glycotope Gmbh | Novel therapeutic treatments with anti-HER2 antibodies having a low fucosylation |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
EP2945964A2 (en) | 2013-01-18 | 2015-11-25 | Glycotope GmbH | Fusion peptides for enhancing protein expression |
KR20160002713A (ko) | 2013-02-13 | 2016-01-08 | 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 | 고도로 갈락토실화된 항-tnf-알파 항체 및 이의 용도 |
US20160002330A1 (en) * | 2013-02-13 | 2016-01-07 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Cetuximab with modified glycosylation and uses thereof |
KR20160003634A (ko) * | 2013-02-13 | 2016-01-11 | 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 | 고도로 갈락토실화된 항-her2 항체 및 이의 용도 |
AR094778A1 (es) | 2013-02-13 | 2015-08-26 | Laboratoire Français Du Fractionnement Et Des Biotechnologies | Proteínas con glicosilación modificada y métodos para producirlas |
SG11201507230PA (en) | 2013-03-12 | 2015-10-29 | Abbvie Inc | Human antibodies that bind human tnf-alpha and methods of preparing the same |
US9371374B2 (en) | 2013-03-14 | 2016-06-21 | Abbott Laboratories | HCV core lipid binding domain monoclonal antibodies |
US9217168B2 (en) | 2013-03-14 | 2015-12-22 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
US9499614B2 (en) | 2013-03-14 | 2016-11-22 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides |
US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
CN105228649B (zh) | 2013-03-14 | 2019-01-18 | 雅培制药有限公司 | Hcv抗原-抗体组合测定和方法以及用在其中的组合物 |
MX2015012824A (es) | 2013-03-14 | 2016-06-24 | Abbott Lab | Antigenos recombinantes ns3 del vhc y mutantes de los mismos para la deteccion mejorada de anticuerpos. |
TW201940691A (zh) * | 2013-03-15 | 2019-10-16 | 美商艾爾德生物製藥股份有限公司 | 抗體純化及純度監測 |
MX2015014773A (es) | 2013-04-22 | 2016-03-04 | Glycotope Gmbh | Tratamientos anti-cancer con anticuerpos anti-egfr que tienen una fucosilacion baja. |
US10208125B2 (en) * | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
US9598667B2 (en) | 2013-10-04 | 2017-03-21 | Abbvie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
BR112016014830A2 (pt) | 2013-12-23 | 2017-09-19 | Bayer Pharma AG | Conjugados de fármaco de anticorpo (adcs) com inibidores de ksp |
EP3113781B1 (en) * | 2014-03-05 | 2018-11-21 | Ultragenyx Pharmaceutical Inc. | Sialylated glycoprotein compositions and uses thereof |
US20150307546A1 (en) * | 2014-04-29 | 2015-10-29 | Georgia Tech Research Corporation | Thermo-responsive lectin-elp fusion binding ligands for glycoprotein purification by affinity precipitation |
CN105820248A (zh) * | 2015-01-07 | 2016-08-03 | 上海张江生物技术有限公司 | 一种新型抗egfr单克隆抗体的制备方法及应用 |
LU92659B1 (en) | 2015-02-23 | 2016-08-24 | Glycotope Gmbh | Glycooptimized antibody drug conjugates |
ES2764457T3 (es) | 2015-03-31 | 2020-06-03 | Glycotope Gmbh | Vectores de expresión eucariotas que incluyen elementos reglamentarios de los grupos de genes de globina |
FR3034420A1 (fr) | 2015-03-31 | 2016-10-07 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-cd303 |
WO2016198499A1 (en) | 2015-06-09 | 2016-12-15 | Glycotope Gmbh | IMPROVED METHOD FOR PRODUCTION OF γ-CARBOXYLATED POLYPEPTIDES |
CN108025084A (zh) | 2015-06-22 | 2018-05-11 | 拜耳医药股份有限公司 | 具有酶可裂解基团的抗体药物缀合物(adc)和抗体前药缀合物(apdc) |
JP2018528161A (ja) | 2015-06-23 | 2018-09-27 | バイエル ファーマ アクチエンゲゼルシャフト | Ksp阻害剤との部位特異的均一複合体 |
WO2016207328A1 (en) | 2015-06-24 | 2016-12-29 | Glycotope Gmbh | PROCESS FOR THE PURIFICATION OF γ-CARBOXYLATED POLYPEPTIDES |
WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
US20170114127A1 (en) | 2015-10-22 | 2017-04-27 | Massachusetts Institute Of Technology | Vegf-a-binding proteins and her2-binding proteins with enhanced stability against aggregation |
WO2017162733A1 (en) * | 2016-03-22 | 2017-09-28 | Glycotope Gmbh | Iga antibodies with enhanced stability |
MX2018011627A (es) | 2016-03-24 | 2019-01-10 | Bayer Pharma AG | Profarmacos de farmacos citotoxicos que tienen grupos enzimaticamente escindibles. |
WO2017216028A1 (en) | 2016-06-15 | 2017-12-21 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies |
EP3472338B1 (en) | 2016-06-20 | 2024-05-22 | Octapharma AG | Means and methods for modifying multiple alleles |
FR3060394B1 (fr) | 2016-12-16 | 2019-05-24 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Combinaison d'anticorps anti-cd303 et anti-amhrii |
FR3060395B1 (fr) | 2016-12-16 | 2019-05-24 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Combinaison d'anticorps anti-cd303 et anti-her2 |
MX2019007641A (es) | 2016-12-21 | 2019-09-09 | Bayer Pharma AG | Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente. |
EP3558387B1 (de) | 2016-12-21 | 2021-10-20 | Bayer Pharma Aktiengesellschaft | Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren |
EP3558386A1 (de) | 2016-12-21 | 2019-10-30 | Bayer Aktiengesellschaft | Prodrugs von cytotoxischen wirkstoffen mit enzymatisch spaltbaren gruppen |
WO2018138113A1 (en) | 2017-01-27 | 2018-08-02 | Glycotope Gmbh | Anti-cancer treatments with an anti-muc1 antibody and an erbb inhibitor |
JP6829357B2 (ja) * | 2017-03-17 | 2021-02-10 | 住友ベークライト株式会社 | 抗体の糖鎖検出法 |
JP2020511959A (ja) | 2017-03-29 | 2020-04-23 | グリコトープ ゲーエムベーハー | ヒト化抗cd40抗体 |
AU2018241781A1 (en) | 2017-03-29 | 2019-07-18 | Glycotope Gmbh | Multispecific antibody constructs binding to MUC1 and CD3 |
EP3601349A1 (en) * | 2017-03-29 | 2020-02-05 | Glycotope GmbH | Pd-l1 and ta-muc1 antibodies |
BR112020004531A2 (pt) | 2017-09-06 | 2020-09-08 | Airway Therapeutics, LLC | métodos, composições e células para preparar proteína surfactante d (sp-d) |
MX2020002552A (es) * | 2017-09-06 | 2020-07-20 | Airway Therapeutics Inc | Métodos y composiciones para preparar proteína surfactante d (sp-d). |
US20210107961A1 (en) * | 2018-03-01 | 2021-04-15 | Glycotope Gmbh | Fusion Protein Constructs Comprising an Anti-MUC1 Antibody and IL-15 |
CN117815404A (zh) | 2018-05-18 | 2024-04-05 | 第一三共株式会社 | 抗-muc1抗体-药物缀合物 |
PE20221770A1 (es) | 2019-12-06 | 2022-11-11 | Regeneron Pharma | Composiciones de proteina anti-vegf y metodos para producir la misma |
WO2022002887A1 (en) | 2020-06-30 | 2022-01-06 | Glycotope Gmbh | Humanized antibodies against lewis y |
WO2023175117A1 (en) | 2022-03-16 | 2023-09-21 | Glycotope Gmbh | Antibodies against lypd3 |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4966843A (en) * | 1982-11-01 | 1990-10-30 | Cetus Corporation | Expression of interferon genes in Chinese hamster ovary cells |
AU2353384A (en) * | 1983-01-19 | 1984-07-26 | Genentech Inc. | Amplification in eukaryotic host cells |
KR850004274A (ko) | 1983-12-13 | 1985-07-11 | 원본미기재 | 에리트로포이에틴의 제조방법 |
US4931275A (en) | 1985-12-02 | 1990-06-05 | Yeda Research & Development Co., Ltd. | Anti-tumor vaccines and their preparation |
US5683674A (en) | 1987-01-07 | 1997-11-04 | Imperial Cancer Research Technology Ltd. | Antibody against human mucin core protein and method of preparing and using same |
EP0573551B1 (en) | 1991-02-27 | 2003-05-21 | Micromet AG | Serine-rich peptide linkers |
JP3698370B2 (ja) | 1992-04-13 | 2005-09-21 | ダナ−ファーバー キャンサー インスティチュート インク | 癌腫抗原用抗体 |
US5804187A (en) | 1992-11-16 | 1998-09-08 | Cancer Research Fund Of Contra Costa | Modified antibodies with human milk fat globule specificity |
ATE301201T1 (de) | 1993-06-07 | 2005-08-15 | Vical Inc | Für die gentherapie verwendbare plasmide |
DE4329004A1 (de) | 1993-08-28 | 1995-03-09 | Max Delbrueck Centrum | Monoklonale Antikörper gegen das Thomsen-Friedenreich-Antigen, ihre Herstellung und ihre Verwendung zum Tumornachweis |
WO1995010538A1 (en) * | 1993-10-15 | 1995-04-20 | The University Of North Carolina At Chapel Hill | Dna encoding the human p2u receptor and null cells expressing p2u receptors |
US5997873A (en) | 1994-01-13 | 1999-12-07 | Mount Sinai School Of Medicine Of The City University Of New York | Method of preparation of heat shock protein 70-peptide complexes |
US5961979A (en) | 1994-03-16 | 1999-10-05 | Mount Sinai School Of Medicine Of The City University Of New York | Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens |
US5888773A (en) * | 1994-08-17 | 1999-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Method of producing single-chain Fv molecules |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
CA2225460A1 (en) | 1995-06-23 | 1997-01-09 | Winston Campbell Patterson | Transcriptional regulation of genes encoding vascular endothelial growth factor receptors |
GB9603256D0 (en) * | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
EP0906444A1 (de) | 1996-04-19 | 1999-04-07 | Gabriele Pecher | Gentransfizierte humane dendritische zellen, ihre herstellung und ihre verwendung, bevorzugt als vakzine |
EP1032428B1 (en) | 1997-11-20 | 2003-06-18 | Vical Incorporated | Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor |
US5948646A (en) | 1997-12-11 | 1999-09-07 | Fordham University | Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes |
ATE458007T1 (de) | 1998-04-20 | 2010-03-15 | Glycart Biotechnology Ag | Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität |
AUPP816899A0 (en) | 1999-01-14 | 1999-02-11 | Food Technology Innovations Pty Limited | Improved microbial products |
JP2003524395A (ja) | 1999-03-02 | 2003-08-19 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | 細胞内シアリル化経路の操作 |
JP4488579B2 (ja) * | 1999-03-30 | 2010-06-23 | 日本たばこ産業株式会社 | モノクローナル抗体の製造方法 |
DK1167537T3 (da) * | 1999-03-30 | 2008-11-10 | Japan Tobacco Inc | Fremgangsmåde til fremstilling af et monoklonalt antistof |
CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Hakko Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
EP1204423B1 (en) | 1999-08-18 | 2005-03-16 | AltaRex Medical Corp. | Therapeutic antibody against muc-1 antigen and methods for their use |
US7147850B2 (en) | 1999-08-18 | 2006-12-12 | Altarex Medical Corp. | Therapeutic binding agents against MUC-1 antigen and methods for their use |
JP2003510334A (ja) | 1999-09-30 | 2003-03-18 | コリクサ コーポレイション | 癌及び感染症の予防及び治療のためのストレスタンパク質組成物及び方法 |
FR2809312B1 (fr) | 2000-05-25 | 2002-07-12 | Gervais Danone Sa | Utilisation de l. casei dans des compositions immunostimulantes |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
CA2424977C (en) * | 2000-10-06 | 2008-03-18 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
GB0029360D0 (en) | 2000-12-01 | 2001-01-17 | Univ Nottingham | Humanised antibodies and uses thereof |
US7510735B2 (en) | 2001-02-01 | 2009-03-31 | Kabushiki Kaisha Yakult Honsha | Method of evaluating the extent of reaching the intestine of bifidobacterium in fermented milk food or drink |
AU2002336981A1 (en) * | 2001-08-17 | 2003-03-03 | Charite | Glycoconjugates of sialic acid derivates, methods for their production and use thereof |
DE10139428A1 (de) | 2001-08-17 | 2003-03-27 | Nemod Immuntherapie Ag | Herstellung und Verwendung von humanen CD124 und CD116 positiven Tumorzelllinien zur Herstellung von allogenen oder semi-allogenen Immuntherapeutika |
CA2464368A1 (en) * | 2001-10-22 | 2003-05-01 | Applied Research Systems Ars Holding N.V. | Compositions of fsh with high sialylation degree and their use for the preparation of medicaments |
GB0125473D0 (en) | 2001-10-24 | 2001-12-12 | Syngenta Ltd | Chemical process |
JP2005517389A (ja) | 2001-11-20 | 2005-06-16 | アトゲン カンパニー リミティッド | 環境ストレス耐性を有する新規のペプチド及びこれを含む融合蛋白質 |
SI1529060T1 (sl) | 2002-07-22 | 2015-01-30 | Glycotope Gmbh | Postopek za proizvodnjo imunostimulacijskih mucinov (MUCI) |
SI1530628T1 (sl) | 2002-08-16 | 2011-02-28 | Glycotope Gmbh | Postopek za proizvodnjo s temperaturo induciranih lizatov tumorskih celic za uporabo kot imunogenske spojine |
DE10256900A1 (de) | 2002-11-29 | 2004-06-24 | Nemod Immuntherapie Ag | Tumorspezifische Erkennungsmoleküle |
DE10303664A1 (de) | 2003-01-23 | 2004-08-12 | Nemod Immuntherapie Ag | Erkennungsmoleküle zur Behandlung und Detektion von Tumoren |
WO2005019258A2 (en) | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
US8017388B2 (en) | 2003-08-18 | 2011-09-13 | Glycotope Gmbh | Tumour cell lines and uses thereof |
FR2861080B1 (fr) | 2003-10-20 | 2006-02-17 | Lab Francais Du Fractionnement | Anticorps presentant un taux de fucose et de galactose optimise |
US20050203010A1 (en) * | 2003-11-14 | 2005-09-15 | Atgen Co., Ltd. | Novel peptides conferring environmental stress resistance and fusion proteins including said peptides |
CA2557725C (en) | 2004-02-13 | 2015-06-30 | Glycotope Gmbh | Highly active glycoproteins-process conditions and an efficient method for their production |
EP1789027B1 (en) | 2004-07-26 | 2013-09-04 | The Research Foundation Of State University Of New York | Therapeutic use of anti-tf-antigen antibody |
EP1987518A1 (en) * | 2006-02-14 | 2008-11-05 | Koninklijke Philips Electronics N.V. | Bit detection for optical disc reading |
WO2007124992A1 (en) | 2006-04-28 | 2007-11-08 | Unilever N.V. | Method of manufacturing a cultured edible product comprising omega-3 polyunsaturated fatty acids |
BRPI0716997B8 (pt) | 2006-09-10 | 2021-05-25 | Glycotope Gmbh | proteína ou composição de moléculas de proteína, métodos para produção e uso da mesma |
EP1900750A1 (en) | 2006-09-18 | 2008-03-19 | Glycotope Gmbh | Fully human high yield production system for improved antibodies |
EP1911766A1 (en) | 2006-10-13 | 2008-04-16 | Glycotope Gmbh | Use of human cells of myeloid leukaemia origin for expression of antibodies |
PL1920781T3 (pl) | 2006-11-10 | 2015-06-30 | Glycotope Gmbh | Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów |
US8741365B2 (en) | 2008-05-13 | 2014-06-03 | Glycotope Gmbh | Fermentation process |
WO2010119691A1 (ja) | 2009-04-16 | 2010-10-21 | 国立大学法人東京大学 | 抗tmprss11e抗体を用いた癌の診断と治療 |
EP2281844A1 (en) | 2009-07-31 | 2011-02-09 | Glycotope GmbH | MUC 1 antibodies |
EP2945964A2 (en) | 2013-01-18 | 2015-11-25 | Glycotope GmbH | Fusion peptides for enhancing protein expression |
JP2015138634A (ja) | 2014-01-22 | 2015-07-30 | 株式会社オートネットワーク技術研究所 | 端子金具付き電線及びその製造方法 |
-
2007
- 2007-09-10 BR BRPI0716997A patent/BRPI0716997B8/pt active IP Right Grant
- 2007-09-10 DK DK07818090.8T patent/DK2073842T4/da active
- 2007-09-10 KR KR1020157031066A patent/KR20150126730A/ko active Application Filing
- 2007-09-10 KR KR1020097007469A patent/KR101603632B1/ko active IP Right Grant
- 2007-09-10 MX MX2009002388A patent/MX2009002388A/es active IP Right Grant
- 2007-09-10 KR KR1020177004543A patent/KR20170021375A/ko not_active Application Discontinuation
- 2007-09-10 EP EP11176193A patent/EP2428223A3/en not_active Withdrawn
- 2007-09-10 RS RS20150158A patent/RS53861B1/en unknown
- 2007-09-10 DK DK11176197.9T patent/DK2428224T3/en active
- 2007-09-10 WO PCT/EP2007/007877 patent/WO2008028686A2/en active Application Filing
- 2007-09-10 FI FIEP07818090.8T patent/FI2073842T4/fi active
- 2007-09-10 CA CA2662226A patent/CA2662226C/en active Active
- 2007-09-10 EA EA200970263A patent/EA017622B1/ru not_active IP Right Cessation
- 2007-09-10 CN CN201310176217.3A patent/CN103436574B/zh active Active
- 2007-09-10 ES ES11176197.9T patent/ES2620261T3/es active Active
- 2007-09-10 SI SI200731634T patent/SI2073842T1/sl unknown
- 2007-09-10 EP EP18188122.8A patent/EP3539981A1/en not_active Withdrawn
- 2007-09-10 AU AU2007294122A patent/AU2007294122B2/en active Active
- 2007-09-10 SG SG2011064987A patent/SG174792A1/en unknown
- 2007-09-10 ES ES07818090T patent/ES2533964T5/es active Active
- 2007-09-10 PT PT78180908T patent/PT2073842E/pt unknown
- 2007-09-10 PL PL07818090T patent/PL2073842T3/pl unknown
- 2007-09-10 EP EP20110176200 patent/EP2428225A3/en not_active Ceased
- 2007-09-10 NZ NZ575974A patent/NZ575974A/en not_active IP Right Cessation
- 2007-09-10 US US12/440,562 patent/US9051356B2/en active Active
- 2007-09-10 JP JP2009527066A patent/JP5767779B2/ja active Active
- 2007-09-10 EP EP11176197.9A patent/EP2428224B1/en active Active
- 2007-09-10 EP EP07818090.8A patent/EP2073842B2/en active Active
-
2009
- 2009-03-08 IL IL197459A patent/IL197459A/en active IP Right Grant
- 2009-03-10 CU CU20090033A patent/CU23791A3/es active IP Right Grant
-
2010
- 2010-03-17 ZA ZA2010/01903A patent/ZA201001903B/en unknown
-
2015
- 2015-03-18 HR HRP20150307TT patent/HRP20150307T1/hr unknown
- 2015-03-27 CY CY20151100305T patent/CY1116279T1/el unknown
- 2015-04-23 JP JP2015088247A patent/JP6166303B2/ja active Active
- 2015-05-04 US US14/703,498 patent/US10280230B2/en active Active
-
2017
- 2017-04-26 JP JP2017087053A patent/JP2017123879A/ja not_active Withdrawn
-
2019
- 2019-04-05 US US16/376,174 patent/US20190359731A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0716997B8 (pt) | proteína ou composição de moléculas de proteína, métodos para produção e uso da mesma | |
BRPI0620803B8 (pt) | anticorpo isolado ou fragmento de anticorpo anti-her-3, seu processo de preparação, composição farmacêutica e kit compreendendo o mesmo, molécula de ácido nucléico codificando o referido anticorpo, vetor compreendendo o mesmo, microrganismo transgênico, bem como método para diagnosticar uma doença associada a her-3 | |
Kim et al. | A clean, more efficient method for in-solution digestion of protein mixtures without detergent or urea | |
BRPI0706801B8 (pt) | método de purificação de cardiomiócitos ou cardiomiócitos programados derivado de células-tronco ou fetos | |
EA201890763A1 (ru) | Библиотеки вариантных олигонуклеиновых кислот и их синтез | |
BR112012007821A2 (pt) | polipeptídeos para ligação ao "receptor de produtos finais de glicação avançada" bem como composições e métodos envolvendo os mesmos | |
WO2007130453A3 (en) | Non-natural amino acid substituted polypeptides | |
Ota et al. | Biochemical characterization of Pumilio1 and Pumilio2 in Xenopus oocytes | |
Choi et al. | Enhanced peptide detection toward single-neuron proteomics by reversed-phase fractionation capillary electrophoresis mass spectrometry | |
WO2009026393A3 (en) | Amino acid substituted molecules | |
BR112015017354A2 (pt) | método para detectar pelo menos uma base modificada | |
BR112021025130A2 (pt) | Reagentes e métodos para replicação, transcrição e tradução em organismos semissintéticos | |
Kotliński et al. | Histone H1 variants in Arabidopsis are subject to numerous post-translational modifications, both conserved and previously unknown in histones, suggesting complex functions of H1 in plants | |
DE602005025401D1 (de) | Hes verfahren unter verwendung davon | |
Sedlák et al. | Photolabeling of cardiolipin binding subunits within bovine heart cytochrome c oxidase | |
BR112014019277A8 (pt) | Populações de células-tronco estromais, tecidos, métodos de isolamento de células-tronco estromais, método de obtenção de tecido, ensaio e método para condução de ensaio e composição farmacêutica | |
Zeng et al. | Proteomic analysis of SARS associated coronavirus using two-dimensional liquid chromatography mass spectrometry and one-dimensional sodium dodecyl sulfate-polyacrylamide gel electrophoresis followed by mass spectroemtric analysis | |
Liu et al. | A multiplex fragment-ion-based method for accurate proteome quantification | |
Li et al. | Comprehensive evaluation of different TiO2-based phosphopeptide enrichment and fractionation methods for phosphoproteomics | |
Kristl et al. | Comparison of different mobilization strategies for capillary isoelectric focusing of ovalbumin variants | |
BRPI0406265B8 (pt) | método para análise por eletroforese capilar, método para pesquisa e tipagem de proteínas monoclonais, método de preparação de anticorpos modificados sobrecarregados negativamente e kit para detecção e tipagem de proteínas monoclonais | |
BR112022010445A2 (pt) | Polímero biomolecular multifuncional, multiespecífico, multimérico , método para preparar um polímero biomolecular multifuncional, multiespecífico, multimérico | |
Zhang et al. | Protein arginine allylation and subsequent fluorophore targeting | |
Magdeldin et al. | Differential proteomic shotgun analysis elucidates involvement of water channel aquaporin 8 in presence of α-amylase in the colon | |
Meyfour et al. | Common proteomic technologies, applications, and their limitations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/06/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/09/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |